Ziihera FDA approval unlocks $250m for Zymeworks as Jazz expands HER2 drug into first-line gastric cancer

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has received U.S. Food and Drug Administration (FDA) approval for two Ziihera-based regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, expanding zanidatamab from a relatively small biliary tract cancer franchise into a considerably larger front-line oncology opportunity. The approval also triggers a US$250 million milestone payment from Jazz to Zymeworks Inc. (NASDAQ: ZYME), which originally developed the bispecific HER2 antibody.

The FDA approved Ziihera, or zanidatamab-hrii, with Tevimbra and fluoropyrimidine- and platinum-containing chemotherapy for HER2-positive tumors classified as IHC 3+ or IHC 2+/ISH+. It also approved Ziihera with chemotherapy without Tevimbra for the narrower IHC 3+ population.

For the triplet regimen, approval applies regardless of PD-L1 status, potentially broadening the eligible population beyond treatment strategies that depend heavily on PD-L1 expression. Jazz had already prepared for an immediate U.S. launch following approval, turning August 25 from a regulatory catalyst into a commercial expansion point for a product that generated only US$15 million of second-quarter sales in its existing biliary tract cancer indication.

How much did Ziihera improve progression-free and overall survival in HER2-positive GEA?

The approval is supported by the Phase 3 HERIZON-GEA-01 trial, which compared Ziihera-containing regimens with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma. Both Ziihera combinations significantly improved progression-free survival in the overall HER2-positive population.

Median progression-free survival reached 12.4 months with the Ziihera-containing regimens compared with 8.1 months in the control group. That represents an improvement of approximately 4.3 months, while the risk of disease progression or death was reduced by 35%.

The overall-survival result for the Ziihera, Tevimbra and chemotherapy triplet was more consequential. Median overall survival reached 26.4 months compared with 19.2 months for trastuzumab plus chemotherapy, an improvement of 7.2 months. The triplet reduced the risk of death by 28%.

Jazz described the 26.4-month median as the longest reported in a Phase 3 trial in this treatment setting. The company also said progression-free and overall-survival benefits were generally consistent across major prespecified subgroups, including patients divided by PD-L1 status and geographic region.

The distinction between the two approved regimens remains important. The strongest disclosed overall-survival finding is associated with the Tevimbra-containing triplet, while the chemotherapy-only Ziihera regimen has its own approved HER2-defined patient population. The approval should therefore not be simplified into a claim that every Ziihera combination produced the same survival outcome.

Why could the first-line approval be much larger commercially than Ziihera’s existing business?

Ziihera was already approved in the United States for previously treated HER2-positive biliary tract cancer, giving Jazz an operating commercial infrastructure and established physician familiarity before the gastroesophageal launch. Second-quarter 2026 Ziihera net product sales in biliary tract cancer were approximately US$15 million, up from US$13 million in the first quarter.

That creates an annualized sales run rate of roughly US$60 million based purely on the second-quarter figure, although quarterly revenue should not be treated as a forecast.

First-line gastroesophageal adenocarcinoma is a significantly broader opportunity. Gastroesophageal adenocarcinoma includes cancers of the stomach, gastroesophageal junction and esophagus, and approximately 20% of patients are estimated to have HER2-positive disease. More than 31,000 new stomach cancer cases alone are diagnosed annually in the United States.

Not every patient will be eligible for or receive Ziihera, and prevalence statistics cannot be converted directly into a revenue forecast. The commercial shift is nevertheless clear: Jazz can now position the drug at initial systemic treatment rather than waiting for disease progression and prior therapy in a comparatively rare biliary cancer population.

First-line placement can also extend treatment duration and increase the number of eligible patients encountered by oncologists, although actual sales will depend on reimbursement, guideline adoption, physician behaviour, competing regimens and safety management.

Jazz’s existing biliary tract launch may help. Management said before approval that its commercial organization was already prepared to launch Ziihera immediately in first-line GEA, reducing the need to build an entirely new field infrastructure after the regulatory decision.

What does the $250m FDA milestone mean for Zymeworks?

The approval has an immediate financial consequence for Zymeworks that is unusually large relative to the biotechnology company’s current operating scale. Under its licensing arrangement with Jazz, FDA approval in first-line HER2-positive GEA triggers a US$250 million milestone payment.

Zymeworks ended June with US$322.5 million of cash, cash equivalents and marketable securities. The US$250 million approval milestone is equivalent to approximately 77.5% of that quarter-end liquidity position, illustrating why the FDA decision matters to Zymeworks even though Jazz controls U.S. commercialization.

The milestone also dwarfs Zymeworks’ normal quarterly revenue. The company generated US$4.6 million in total second-quarter revenue, including approximately US$1.8 million of royalty revenue from Jazz and BeOne Medicines driven primarily by commercial sales of Ziihera.

The US$250 million payment is therefore more than 50 times Zymeworks’ entire second-quarter revenue, although milestone income is non-recurring and should not be treated as a new quarterly run rate.

Zymeworks remains eligible for additional economics. Its August 25 announcement says it could receive up to US$1.3 billion of further regulatory and commercial milestones from Jazz, together with tiered royalties reaching 20% on applicable net sales. Through its BeOne collaboration covering parts of Asia-Pacific, it remains eligible for up to another US$144 million of milestones and royalties reaching as high as 19.5%.

That makes Ziihera increasingly important as a funding asset for a company whose own strategy now combines internal drug development, royalty income, acquisitions and capital returns.

How much of Zymeworks’ future Ziihera royalty stream has already been monetized?

Zymeworks made another important financial decision before the first-line FDA approval. In March, it raised US$250 million from Royalty Pharma through a non-recourse royalty-backed note secured by a portion of future Ziihera royalties.

Under the structure, Royalty Pharma receives 30% of worldwide tiered Ziihera royalties owed to Zymeworks until defined repayment thresholds are reached. Zymeworks retains 70% of the royalty stream during that period, with its full royalty rights reverting after the financing has been satisfied.

The repayment ceiling is structured around cumulative payments equal to 1.65 times the note amount by December 31, 2033, or 1.925 times if repayment extends beyond that date. Once the applicable threshold is achieved, Royalty Pharma ceases receiving the pledged share.

Crucially, Zymeworks retained its milestone economics. The company specifically said regulatory and commercial milestone payments under the Jazz and BeOne collaborations are not pledged to the Royalty Pharma note, meaning the US$250 million FDA-triggered milestone remains with Zymeworks rather than being diverted to repay the royalty financing.

That arrangement gives Zymeworks an interesting financial profile. It already monetized part of the future royalty stream for US$250 million upfront, has now triggered another US$250 million regulatory milestone and still retains most ongoing royalties plus significant additional milestone potential.

What does the approval mean financially for Jazz Pharmaceuticals?

Jazz is the company responsible for commercializing Ziihera in the United States and several other markets, so it bears both the US$250 million milestone expense and the commercial upside from the expanded indication.

The drug is still small relative to Jazz’s overall revenue base. Jazz generated record second-quarter revenue of approximately US$1.2 billion, while Ziihera contributed US$15 million of net product sales from biliary tract cancer. Ziihera therefore represented only about 1.3% of quarterly company revenue before the new indication.

That is exactly why the first-line approval matters strategically. Mature Jazz products such as Xywav and Epidiolex already generate hundreds of millions of dollars per quarter, while newer oncology drugs need to build enough scale to diversify the portfolio over time.

Jazz raised its 2026 revenue guidance after second-quarter results and had already highlighted first-line Ziihera as one of the important future growth drivers. The company now has a regulatory label supported by a 7.2-month median overall-survival improvement for the triplet regimen, giving its commercial organization a clinically differentiated message as it approaches oncologists treating HER2-positive advanced disease.

The economics are not cost-free. Jazz owes milestones and royalties to Zymeworks and operates the clinical, regulatory and commercial programme. A successful launch therefore needs to generate enough sales and margin to compensate for those licensing costs.

What safety considerations could influence Ziihera adoption?

The U.S. prescribing information carries boxed warnings for diarrhea and embryo-fetal toxicity. Severe, life-threatening and fatal diarrhea can occur when Ziihera is used with chemotherapy, with or without Tevimbra, despite preventive treatment.

Jazz instructs clinicians to use loperamide prophylaxis during the first treatment cycle and to manage subsequent diarrhea with antidiarrheal therapy, fluids, electrolytes and dose modifications when required. The company said diarrhea was the most common adverse reaction in HERIZON-GEA-01 and was generally concentrated early in treatment.

The risk was higher with the Tevimbra-containing triplet, particularly among patients aged 65 and older. That creates a practical clinical trade-off because the triplet is also the regimen associated with the strongest disclosed overall-survival benefit.

Real-world adoption will therefore depend not only on efficacy but on how comfortably oncology practices manage the toxicity profile, particularly in older patients who can already be medically fragile because of advanced gastroesophageal cancer.

Why is August 25 more than a routine FDA approval for Ziihera?

The approval changes three things at once. For patients and physicians, it adds first-line HER2-directed regimens supported by statistically significant progression-free survival improvement and a major overall-survival result for the triplet.

For Jazz, it moves Ziihera from a US$15 million-per-quarter niche oncology product toward a much broader commercial market and strengthens a franchise management hopes will become increasingly important alongside its established neuroscience businesses.

For Zymeworks, it turns years of partnered development into immediate financial leverage. A US$250 million approval milestone is now triggered, further milestones remain available and recurring royalties can expand as sales move beyond biliary tract cancer.

Those interests are linked but not identical. Jazz has to prove commercial adoption can justify development, milestone and royalty costs. Zymeworks has already captured a large part of the financial benefit without having to build the U.S. commercial organization itself.

The FDA decision therefore does more than add an indication to a label. It converts HERIZON-GEA-01’s survival data into a much larger economic test of zanidatamab, with the next evidence coming not from another regulatory headline but from how quickly first-line adoption begins appearing in Ziihera sales.